US 11077079

I'll search for authoritative information on this specific patent number.

Let me verify the actual claims and check for any Court of Appeals for the Federal Circuit (CAFC) docket activity.

Let me check the Federal Circuit appeal outcome and any 2026 docket activity for this patent.

US Patent 11,077,079 B1 — Analyst Summary

Sourcing note: I pulled this from the authoritative Google Patents full text you supplied, plus public litigation/regulatory filings (CourtListener, docket records, PACER-derived summaries). I was not able to log into USPTO PatentCenter/PAIR directly in this session, and I found no CAFC 2026 docket tied specifically to this patent (see "Litigation" below). Where I lack authoritative text, I say so explicitly.

Bibliographic Data

Continuity chain (as stated): 17/118,041 ← 16/448,598 (filed Jun. 21, 2019, abandoned) ← 15/047,586 (filed Feb. 18, 2016, now US 10,398,662) ← provisional 62/117,889 (Feb. 18, 2015).
Family members noted: US 11,147,782 B1 (continuation, App. 17/210,064, filed Mar. 23, 2021); US 11,364,215 B1 (App. 17/222,579, filed Apr. 5, 2021); US 2024/0016770 A1 (from App. 18/473,935, filed Sep. 25, 2023). A security interest in the patent was recorded to U.S. Bank National Association on May 5, 2021.

Independent Claims — Plain Language

The '079 patent has two independent claims, claims 1 and 10 (as identified in Avadel's expert report filed in the Delaware litigation). All other claims depend from one of these two.

Claim 1 — A method of treating narcolepsy in a patient, comprising:

• administering a single daily dose containing an amount of oxybate equivalent to 4.0 g to 12.0 g of sodium oxybate;
• where the administering step involves (i) opening a sachet containing a solid oxybate formulation, (ii) mixing it with water, and (iii) orally administering the mixture;
• and the oxybate formulation contains both an immediate-release component and a controlled-release component.

Claim 10 — The same method, but the treated condition is cataplexy or excessive daytime sleepiness associated with narcolepsy (again 4.0–12.0 g sodium oxybate equivalent, single daily dose, sachet opened/mixed with water/orally administered, IR + controlled-release components).

Dependent claims (text as recited in the litigation record):

• 2 / 11: administering occurs at night.
• 3 / 12: formulation is mixed with water immediately prior to administration.
• 5 / 14: administering "promotes the patient to sleep for 6 to 8 hours."
• 6 / 15: amount of oxybate administered is 35, 45, 60, or 70 mEq.
• 7 / 16: the mixture is a suspension.
• 8 / 17: formulation further comprises an acid.
• 9 / 18: acid selected from malic, citric, tartaric, boric, maleic, phosphoric, and benzoic acid.

Uncertainty flag: The record excerpts I retrieved cover claims 1–3, 5–12, and 14–18. I do not have authoritative text for claims 4 and 13 (which were not asserted); they exist but I cannot quote them.

Important Analytical Observation (Specification vs. Claims)

There is a material disconnect between the '079 specification and its granted claims — a point repeatedly litigated:

• The specification (the bulk of the document you supplied) is overwhelmingly directed to drug–ion-exchange resin complexes ("resinates"): loading GHB or its prodrug GBL onto hydroxide-form Type 1 strong-base anion exchange resins, coatings, lipophilic counter-ions, supplemental anions, etc. The Summary of Invention frames nearly every embodiment around polymeric/resin beads.
• The granted claims, by contrast, are method-of-treatment claims reciting a sachet-based solid IR + controlled-release oxybate formulation, with no ion-exchange/resin limitation.

Avadel argued in the Delaware litigation that the asserted claims lack written description support in the '079 specification and were drafted based on Avadel's own published disclosures. Jazz denied these allegations. A district court brief summarizing the dispute notes Jazz's assertion that the "Resinate Patents" ('079/'782) and Avadel's LUMRYZ product involve "different formulation technology." This is an allegation/position in litigation, not an adjudicated finding regarding the '079 patent's validity.

Litigation Status

• Asserted by Jazz against Avadel CNS Pharmaceuticals, LLC in D. Del. C.A. No. 21-1138 (Google Patents also lists D. Del. 1:22-cv-00487). Jazz's infringement contentions asserted claims 1–3, 5–12, and 14–18 of the '079 patent.
• At the February 2024 patent trial in the consolidated action (C.A. No. 21-691), Jazz narrowed its asserted patents to the '488 and '782 patents and asserted claims (including claim 24 of the '782). The '079 patent was therefore not among the patents on which the jury returned its verdict. (The jury found no infringement of the '488 patent and infringement of the '782 patent.)
• Federal Circuit appeal: Case 24-2274 (consolidated with 24-2278), Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, decided May 6, 2025 — "reversed-in-part, vacated-in-part, and remanded," addressing the scope of the permanent injunction (safe harbor for clinical trials, open-label extension, and an idiopathic hypersomnia indication). Google Patents also lists a related appeal at 24-2277. A third-party litigation database lists US 11,077,079 B1 among the "sodium oxybate patents in suit" across the Avadel/Jazz appeals, but the claim actually on appeal concerned the '782 patent — so I would not treat '079 as the patent adjudicated on appeal.
• 2026 docket check: I found no CAFC docket activity in 2026 specifically involving US 11,077,079. The only 2026-relevant items I located are district court matters (e.g., Jazz Pharmaceuticals Ireland Ltd. v. Tris Pharma, Inc., D.N.J. No. 2:26-cv-01739) concerning other Jazz patents (divalproex co-administration method-of-use patents), not the '079 patent. Public reports also indicate a Jazz–Avadel settlement reached around October 21, 2025, with a joint stipulation of dismissal entered in a related docket.
• Google Patents marks the legal status as Active, with anticipated expiration February 18, 2036.

Caveats

• I am an AI patent analyst; this is a technical summary, not legal advice, and not an infringement/validity/FTO opinion.
• The claim paraphrases above are based on claim text quoted in Delaware litigation filings and an expert report, cross-checked against the patent's issue date and title. For the exact, current language of every claim — and any post-issue certificate of correction or reexamination — consult the official USPTO PatentCenter record for US 11,077,079.
• No authoritative 2026 CAFC docket for this patent number was found; if one exists, it did not surface in my searches.

Key sources: Google Patents US11077079B1 (https://patents.google.com/patent/US11077079B1/en); D. Del. Concise Statement of Facts re '079 (https://storage.courtlistener.com/recap/gov.uscourts.ded.77089/gov.uscourts.ded.77089.341.0.pdf); D. Del. Joint Supplemental Claim Construction Appendix (Georgetown Litigation Tracker); D. Del. 21-691 summary judgment briefing; Fed. Cir. 24-2274 opinion, decided May 6, 2025 (https://cases.justia.com/federal/appellate-courts/cafc/24-2274/24-2274-2025-05-06.pdf).

I'll research litigation involving US patent 11077079. Let me start with several searches.

Let me dig into the specific case numbers referenced on the patent page.

Let me get details on the specific cases and their outcomes.

Litigation involving U.S. Patent No. 11,077,079 ("the '079 patent")

Important caveat up front: The '079 patent (Jazz Pharmaceuticals Ireland Ltd.; filed Dec. 10, 2020; issued Aug. 3, 2021; priority Feb. 18, 2015) has no separate, stand‑alone litigation docket of its own. It was asserted (and its validity challenged) as one patent within the larger, long‑running Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals Hatch‑Waxman/knowledge dispute, which was litigated as a consolidated Delaware action. Below is what the record shows, with the identifiers exactly as they appear.

1. Jazz Pharmaceuticals, Inc. et al. v. Avadel CNS Pharmaceuticals, LLC (and Avadel Pharmaceuticals plc) — the infringement case that asserted '079

• Plaintiffs: Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited
• Defendants: Avadel CNS Pharmaceuticals, LLC and Avadel Pharmaceuticals plc
• Jurisdiction/Court: U.S. District Court for the District of Delaware (Judge Gregory B. Williams)
• Case No.: 1:21‑cv‑01138‑GBW — this is the "Second Complaint," filed August 4, 2021, and it is the complaint in which Jazz alleged that Avadel's proposed sodium‑oxybate product "FT218"/LUMRYZ would infringe U.S. Patent No. 11,077,079. (Per Avadel/Jazz filings: "On August 4, 2021, Jazz filed another formal complaint (the 'Second Complaint')… alleging that the Proposed Product described in the NDA owned by Avadel CNS will infringe at least one claim of U.S. Patent No. 11077079.")
• Consolidation: 1:21‑cv‑01138‑GBW was consolidated for pretrial purposes with the "First Complaint" case 1:21‑cv‑00691‑GBW (filed May 12, 2021, asserting the "REMS Patent," U.S. Pat. No. 8,731,963) and the "Third Complaint" case 1:21‑cv‑01594‑GBW (filed Nov. 10, 2021, asserting U.S. Pat. No. 11,147,782 — the '782 patent). The three cases carried a shared schedule and were jointly Captioned in the Federal Circuit as "Nos. 21‑0691, 21‑1138, 21‑1594."
• Claims of '079 asserted: Jazz's Dec. 7, 2021 infringement chart asserted claims 1–3, 5–12, and 14–18 of the '079 patent (along with claims 1–24 of the '782 patent).
• Avadel's defenses: non‑infringement and invalidity — lack of written description/enablement, improper inventorship, and anticipation/obviousness over prior art (e.g., U.S. Pub. 2006/0210630 "Liang 2006"; U.S. Pat. No. 8,529,954 "Lebon 2013"; EP 2825188 B1 "Comiskey 2015"; U.S. Pub. 2012/0076865 "Allphin 2012"). Avadel also disputed priority, contending the '079 claims were entitled to no earlier than a Dec. 10, 2020 priority date.
• Procedural history / status:
  • Extensive claim construction and summary‑judgment practice (including Jazz motions for partial summary judgment of non‑obviousness and non‑anticipation directed to the '079 and '782 patents, and Avadel motions for summary judgment of invalidity for lack of enablement).
  • Before trial, Jazz narrowed the asserted patents to the '488 and '782 patents (claim 7 and 11 of the '488 patent and claim 24 of the '782 patent). The '079 patent was therefore not among the claims presented to the jury at the February–March 2024 trial. (Note: I could not confirm from the available sources whether the '079 patent was formally dismissed by stipulation or simply dropped from the case as narrowed; treat that specific point as not fully verified.)
  • Jury verdict, March 4, 2024 (verdict sheet D.I. 564, entered Feb. 28/Mar. 4, 2024): the jury found in Jazz's favor on validity of the '488 and '782 patents and awarded a reasonable royalty of approximately $233,563 for past infringement; Avadel had stipulated to infringement of claim 24 of the '782 patent.
• Outcome/current status: The consolidated Delaware action was ultimately settled. Per Avadel's disclosure: "On October 21, 2025, the parties reached a settlement with respect to this pending case… On October 24, 2025, the parties filed a joint stipulation of dismissal with prejudice, which the Court entered on October 27, 2025." (I could not confirm from the retrieved sources that the Oct. 2025 dismissal specifically covered the '079‑patent assertions versus the case as a whole; the settlement appears to be a global resolution of the pending Jazz–Avadel litigation.)

2. Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. — the follow‑on action referencing '079

• Plaintiffs: Avadel CNS Pharmaceuticals, LLC and Avadel Pharmaceuticals plc
• Defendants: Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited
• Jurisdiction/Court: U.S. District Court for the District of Delaware (Judge Gregory B. Williams)
• Case No.: 1:22‑cv‑00487‑GBW
• Filing Date: April 14, 2022
• Nature: Breach of confidential disclosure agreements / trade‑secret misappropriation / correction of inventorship as to certain Jazz patents (including the '079, '782, and '488 patents), plus antitrust counterclaims. This is the case listed on the '079 patent's Google Patents page (see below).
• Status: Jazz moved to stay this action pending resolution of the patent case; the dispute over staying the case (and Avadel's antitrust counterclaims, which survived Jazz's motions to dismiss in May 2024) was still active into 2024. The October 2025 global settlement/dismissal noted above would resolve this action as well.

3. Appeals — U.S. Court of Appeals for the Federal Circuit

• Appeal Nos. 24‑2274, 24‑2277, and 24‑2278, Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, appealed from D. Del. Nos. 21‑0691, 21‑1138, 21‑1594. (The '079 patent's own Google Patents page links 24‑2277 and 24‑2274.)
• Outcome: Oral argument was heard February 7, 2025; the Federal Circuit issued its opinion on May 6, 2025 (Lourie, Reyna, Taranto) reversing‑in‑part, vacating‑in‑part, and remanding the district court's permanent injunction (which had enjoined Avadel from, inter alia, seeking FDA approval of LUMRYZ for idiopathic hypersomnia and from initiating certain new clinical trials). (These appeals concerned the injunction arising from the '488/'782 side of the litigation; the '079 patent itself was not tried, so no appeal turns directly on a '079 judgment.)

What I did NOT find

• No IPR/PGR (PTAB) proceeding against U.S. Pat. No. 11,077,079 was located in the searches performed.
• No litigation involving the '079 patent outside the Jazz–Avadel Delaware/Federal Circuit dispute was located. (The patent's Google Patents page lists only the two Delaware District Court dockets — 1:21‑cv‑01138 and 1:22‑cv‑00487 — plus the two Federal Circuit appeals, as its "family has litigation.")
• Note: Other Jazz oxybate litigation exists (e.g., Jazz v. Lupin and Jazz v. Teva, D.N.J.; Jazz v. FDA, D.D.C.; and Avadel's 2024–2025 suits against Jazz in D. Del. over newly issued Avadel patents), but those do not involve the '079 patent and should not be confused with it.

Sources

• Google Patents page for US11077079B1 (litigation links to D. Del. 1:21‑cv‑01138 and 1:22‑cv‑00487, and Fed. Cir. 24‑2277 and 24‑2274): https://patents.google.com/patent/[US11077079](/patent/US11077079)/en
• Avadel investor disclosures summarizing the Jazz–Avadel complaints, jury trial, and settlement: https://investors.avadel.com/static-files/fa50e831-dcde-4550-ac10-9814c51d9b5a ; https://investors.avadel.com/static-files/c3fa19da-6738-49cf-808f-7392be12c34e
• CourtListener dockets for D. Del. 1:21‑cv‑00691, 1:21‑cv‑01138, 1:21‑cv‑01594, and 1:22‑cv‑00487 (verdict sheet D.I. 564; summary‑judgment opinion D.I. 526)
• Federal Circuit opinion, May 6, 2025 (24‑2274/24‑2278): https://cases.justia.com/federal/appellate-courts/cafc/24-2274/24-2274-2025-05-06.pdf
• DrugPatentWatch litigation summary for 1:22‑cv‑00487

If you need me to run down the precise termination docket entries (e.g., whether the '079 claims were dismissed by stipulation in 21‑1138 and the exact terms of the October 2025 settlement), tell me and I'll target those PACER/CourtListener filings specifically.

I'll verify the structured data against public sources before concluding.

Let me check for any PTAB filings on the related patents and confirm the absence of IPRs on the '079.

Proceedings overview

Total AIA trial proceedings on file for US 11,077,079: zero (0). Breakdown: 0 active, 0 claims invalidated, 0 claims sustained, 0 settled, 0 institution denied. The structured USPTO Open Data Portal block supplied in this prompt returns no AIA trials, and my independent web checks surfaced no IPR, PGR, or CBM naming the '079 patent as the challenged patent. The litigation and appeal entries that Google Patents lists under this patent's "Family has litigation" flag (D. Del. C.A. Nos. 1:21-cv-01138, 1:22-cv-00487; Fed. Cir. Nos. 24-2274, 24-2277) are Article III district court and appellate matters, not PTAB proceedings — they must not be miscoded as AIA trials.

Bottom line for a defendant: the patent has never been challenged at the PTAB, so it carries no PTAB estoppel baggage and no PTAB-created invalidity history. That cuts both ways — there is no canceled claim to point to, but there is also no adverse PTAB precedent, no IPR-driven claim amendment, and no § 315(e) estoppel constraining anyone. This is an untested patent at the Board, and the Board is a blank slate for a first-mover petitioner.

No proceeding sections to populate

I will not manufacture proceeding numbers (e.g., "IPR2022-xxxxx") to fill the template. There is nothing to report at claim-level granularity because no FWD exists. Any output that quoted claim-by-claim dispositions here would be fabricated.

Context that a defendant actually needs (expressly NOT AIA trials)

The '079 patent's entire adversarial history has run through the district courts and the Federal Circuit, plus related prosecution disputes:

• D. Del. C.A. No. 1:21-cv-01138 (consolidated with 1:21-cv-00691 and 1:21-cv-01594) — Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Ltd. v. Avadel CNS Pharmaceuticals LLC, arising from Avadel's NDA for LUMRYZ. Jazz originally asserted the "SR patents" (U.S. Pat. Nos. 10,758,488; 10,813,885; 10,959,956; 10,966,931) plus the '079 and '782 ("resinate") patents. Per the court's 2024-02-14 memorandum opinion, Jazz narrowed the trial to U.S. Pat. Nos. 10,758,488 and 11,147,782, and to claims 7 and 11 of the '488 patent and claim 24 of the '782 patent. The '079 was therefore not tried. Docket: https://www.courtlistener.com/docket/60111152/jazz-pharmaceuticals-inc-v-avadel-cns-pharmaceuticals-llc/
• Jury verdict, trial 2024-02-26 to 2024-03-04 — jury found the asserted '488 and '782 patents valid and awarded damages. Injunction entered 2024-08-27 (enjoining infringement of claim 24 of the '782 through 2036-02; ongoing royalty above 3.5%).
• Fed. Cir. Nos. 24-2274 and 24-2277 — Avadel's appeal of the injunction/judgment. Argued 2025-02-07; opinion issued 2025-05-06, reversed-in-part, vacated-in-part, and remanded (per Jazz's 10-Q). https://portal.unifiedpatents.com/litigation/Court%20of%20Appeals%20for%20the%20Federal%20Circuit/case/24-2277
• Fed. Cir. No. 2023-1186 — Jazz v. Avadel, 2023 WL 2198640 (Fed. Cir. Feb. 24, 2023) (Lourie, J.), affirming delisting of the REMS patent from the Orange Book. This is a different patent (REMS family), not the '079.
• Avadel's counterclaims in the Delaware case assert derivation/copying — that Jazz copied the '079 and '782 claims from Avadel's published applications ('990/'321 → U.S. Pat. No. 10,952,986; and Avadel's '866) and that the '079 claims lack written description/enablement and are not entitled to the 2015-02-18 provisional date, plus inequitable conduct/unclean hands. These are district-court-only theories — see the estoppel/eligibility point below.

Strategic summary

Claim status. All claims of the '079 patent are UNTESTED by any adjudicator. The patent has independent claims 1 and 10 and dependent claims through at least claim 18 (the litigation record cross-references claims 1–18, including 5, 6, 8, 9, 14, 15, 17, 18). No claim has been canceled, confirmed, or construed in a final merits ruling specific to the '079; the Delaware narrowing removed it from the jury's reach. Claim 1 is a method claim: treating narcolepsy by administering a single daily dose of oxybate equivalent to 4.0–12.0 g sodium oxybate, by opening a sachet, mixing with water, and orally administering, where the formulation comprises an immediate release component and a controlled release component. If your demand letter or complaint cites the '079, note that the earlier Delaware case effectively abandoned it at trial — that is a signal about assertion value, not a validity holding.

Estoppel landscape. Because no petition was ever instituted and no FWD issued, § 315(e)(2) estoppel is empty — there is no petitioner, no privy class, and no ground "raised or reasonably could have been raised" in an IPR. A defendant today can petition freely on any § 102/§ 103 ground built on patents and printed publications, without inheriting anyone else's estoppel and without a General Plastic "follow-on petitioner" risk from an earlier Avadel (or other) petition, because none exists. Note the flip side: the strongest attacks on this patent are structurally IPR-ineligible under § 311(b). Lack of written description, non-enablement, improper inventorship/derivation, and inequitable conduct are not § 102/§ 103 patent-and-printed-publication grounds. IPR can reach the priority date only indirectly (e.g., a § 102/§ 103 challenge using Avadel's pre-2019 publications as art, attacking the effective filing date). That asymmetry may explain the absence of IPRs here and is a reason not to expect one soon.

Pattern signals. No defensive aggregator (e.g., Unified Patents) has filed against the '079, despite Unified's litigation data appearing in the patent's record. The same challenger (Avadel) has pursued district court + counterclaim attack rather than PTAB attack. Jazz has litigated Xyrem-family patents heavily at the PTAB historically — the older REMS/distribution patents were the IPR battlegrounds (six of seven REMS patents held unpatentable in July 2016; an IPR on U.S. Pat. No. 8,772,306 not instituted; a CBM on a Jazz patent in Par Pharm. v. Jazz Pharm.) — but that wave concerned an earlier generation of patents and did not touch the '079. The '079's family is 2036-02-18-expiring and now the subject of Federal Circuit activity (24-2274/24-2277), so expect continued district-court, not PTAB, pressure.

Recommended next steps

1. Do not assert "the PTAB canceled the '079 claims" and do not defend on that basis. The accurate statement is: no AIA trial has ever been filed on US 11,077,079; all claims remain untested. Confirm this yourself against PTAB E2E (https://ptacts.uspto.gov/) and the ODP structured data before any filing or opinion.
2. If you are a defendant now facing the '079 (e.g., a sachet/single-daily-dose theory under claim 1), the viable IPR track is a § 102/§ 103 attack using pre-2016 printed publications, ideally coupled with a priority challenge to the 2016-02-18 effective filing date (the examiner's own prosecution record reportedly states there is "no support for the claimed subject matter" in provisional '889–'889 and that the earliest effective filing date for the claims is 2016-02-18). Written description, enablement, and inventorship arguments belong in district court and cannot be run at the Board.
3. Watch the active non-PTAB clock, not a PTAB clock. The live milestones are the Fed. Cir. remand in Nos. 24-2274/24-2277 (opinion 2025-05-06) and the D. Del. proceedings; there is no institution-decision deadline, no oral hearing, and no statutory one-year FWD date to track because no trial has been instituted.
4. Treat the absence of PTAB activity as a market signal, with a caveat. Well-asserted pharmaceutical patents usually attract IPRs; the '079 has been asserted since 2021 without one. The most likely explanation is the § 311(b) limits (the best defenses are non-IPR-eligible) rather than unassailable prior art — so run a full invalidity search rather than assuming the claims are strong.

Confidence statement: I have high confidence there are no PTAB proceedings on the '079 patent based on the structured ODP data plus the absence of any IPR/PGR/CBM references in the litigation and news record I reviewed. I could not independently verify every related-family patent (e.g., the '488, '885, '956, '931, '782) for PTAB filings, and I am not asserting anything about those. If a recently filed petition post-dates the ODP ingest, it would not appear here; verify directly at PTAB E2E before relying on the zero count in a filing.

I'll research the assignment record for this patent from authoritative sources.

Let me dig deeper into the specific assignment records and the corporate history.

Let me verify the security agreement context and search for the specific reel/frame records.

Assignment & Ownership Analysis — US 11,077,079 B1

Sourcing note (read first): I could not establish an interactive session against USPTO Assignment Center / assignment.uspto.gov in this run, so I was unable to retrieve the reel/frame numbers or the recorded correspondent-of-record for this patent. I will not invent them. What follows is built from (a) the Google Patents "Legal Events / reassignment" tables in the authoritative full text you supplied, which mirror the assignment records, and (b) corroborating public records (PTAB real-party-in-interest notices, SEC filings, court dockets). Where a field is missing, I say so. The verification endpoints are linked in the Verdict section.

Inventors

Unusual-pattern check:

• No inventor departed to a third party. Both assignments ran inward to Jazz (2020-12-14), not outward. There is no evidence of an inventor-side "fire sale" precondition.
• Deceased co-inventor. At least one named inventor appears to be deceased (per the Jazz brief referenced above). This is a prosecution/inventory risk flag (declaration practice under 37 CFR 1.63/1.64), not an NPE flag.
• Inventorship is contested, not settled at the assignment layer. Avadel pleaded that the true inventors were Claire Megret, Hervé Guillard, and Jean-Francois Dubuisson (Avadel-side scientists), i.e., a derivation / §101 / §115(a) theory. This is an allegation in litigation (Avadel's Final Invalidity Contentions), not an adjudicated finding, and it does not change the recorded chain of title.

Original assignee

• Issued-patent assignee of record (face of patent): Jazz Pharmaceuticals Ireland Limited, Connaught House, One Burlington Road, Fourth Floor, Dublin, Ireland.
• Immediate upstream holder: Jazz Pharmaceuticals, Inc., a Delaware corporation (3180 Porter Drive, Palo Alto, CA).
• Primary line of business: commercial pharmaceutical company. Jazz Ireland is the group's NDA/Orange Book-holding entity for the oxybate franchise.
• Product embodying the claims: Jazz ships Xyrem® (sodium oxybate) and Xywav® (mixed-salts oxybate). The asserted claims in the related litigation are method-of-treatment claims aimed at once-nightly oxybate products (Avadel's LUMRYZ). Jazz is an operating company with commercial products and a marketed franchise, not a licensing shell.
• Current status: operating; publicly traded parent Jazz Pharmaceuticals plc (NASDQ: JAZZ; File No. 001-033500). No bankruptcy, dissolution, or receivership in the record.

Assignment timeline

Caveat: The events below are the records surfaced in the Google Patents reassignment table for application 17/118,041. Execution dates are not exposed in that table; the dates shown are the recorded dates. Reel/frame numbers and correspondent-of-record were not retrievable in this session — I have left them as [not retrieved] rather than guess.

• Executed 2020-12-14 (recorded 2020-12-14) — Reel [not retrieved]

  • Conveyance: Assignment (of assignors' interest)
  • Assignor: Scott Bura; Clark Allphin
  • Assignee: Jazz Pharmaceuticals, Inc. (Delaware)
  • Correspondent: [not retrieved]
  • Context: Standard inventor→employer invention assignment; internal/initial vesting, not a third-party transfer.

• Executed ~2020-12-15 (recorded 2020-12-15) — Reel [not retrieved]

  • Conveyance: Assignment
  • Assignor: Jazz Pharmaceuticals, Inc.
  • Assignee: Jazz Pharmaceuticals Ireland Limited
  • Correspondent: [not retrieved] — Note: for sibling Jazz oxybate patents the two-step pattern (inventor→Jazz Inc.→Jazz Ireland) was recorded under Reel 30652/164 → 33480/135 ('302 patent) and Reel 30836/953 → 33480/220 ('306 patent), per Jazz's PTAB §42.8(b)(1) notices. The recurring reel prefix 33480 on those sibling recordings indicates Jazz used a single consistent recording correspondent/firm for its Ireland-transfer step circa 2013–2014. I flag that as a cross-family recurrence observation only — I did not confirm it applies to the '079 reel, so it is not a finding for this patent.
  • Context: Intra-group reorganisation — moving title to the Irish NDA/Orange Book-holding entity. Classic "operating parent → operating subsidiary" housekeeping.

• Executed ~2021-05-05 (recorded 2021-05-05) — Reel [not retrieved]

  • Conveyance: Security Agreement (grant of security interest, not a title transfer)
  • Assignors: Cavion, Inc.; Celator Pharmaceuticals, Inc.; Jazz Pharmaceuticals Ireland Limited; Jazz Pharmaceuticals, Inc.
  • Assignee / secured party: U.S. Bank National Association (as Collateral Trustee)
  • Correspondent: [not retrieved]
  • Context: Securitization. This is the IP-collateral filing for the Credit Agreement dated May 5, 2021 among Jazz Pharmaceuticals plc, the borrowers (incl. Jazz Ireland and Jazz Pharmaceuticals, Inc.), Bank of America as Administrative Agent, and U.S. Bank as Collateral Trustee (later U.S. Bank Trust Company, National Association, as successor). The multi-entity assignor list (Cavion + Celator + Jazz entities) confirms this is a group-wide blanket IP lien tied to the GW Pharmaceuticals acquisition financing — not a transfer of ownership to a third party.

No post-2021 recorded assignments appear in the record. Title remains with Jazz Pharmaceuticals Ireland Limited, encumbered by the U.S. Bank security interest.

Timeline diagram

timeline
    title Ownership of US 11077079
    2015 : Priority date February 18
    2016 : Parent non-provisional filed
    2020 : Continuation filed December 10
         : Inventors assign to Jazz Inc
         : Jazz Inc assigns to Jazz Ireland
    2021 : Patent issues August 3
         : IP collateral lien to US Bank
    2025 : Jazz and Avadel settle

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. The only assignees are Jazz Pharmaceuticals, Inc. (Delaware operating company) and Jazz Pharmaceuticals Ireland Limited (Irish NDA/Orange Book-holding operating entity). No "IP / Holdings / Licensing / Ventures" suffix, no registered-agent-only address, no single-member LLC. Both are named real parties-in-interest in Jazz's PTAB filings at 3180 Porter Drive and Dublin.

2. Known asserter in the chain — NOT PRESENT. None of Acacia, Marathon, IV, IPNav, Wi-LAN, MOSAID/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, DGC, or Spangenberg entities appears anywhere in the chain. The asserter here is Jazz itself, an operating company suing a competitor (Avadel) in its own name.

3. Repeat correspondent across the chain — UNCLEAR. The correspondent-of-record was not retrievable in this session, so I cannot call this either way for the '079 reel. For transparency: the sibling Jazz oxybate patents show a recurring reel prefix (33480) on the Jazz-Inc.→Jazz-Ireland step, which is consistent with a single outside recording firm doing all of Jazz's Ireland transfers — but that is evidence about the Jazz family generally, not about this patent, and Jazz is an operating company, so even if confirmed it would be housekeeping, not an NPE tell.

4. Cascading transfers — NOT PRESENT. Exactly one intra-group hop (Jazz Inc. → Jazz Ireland), recorded 2020-12-15, i.e., a single link, not a chain of consecutive LLC-to-LLC conveyances within 24 months. The only other event is a security interest, which does not move title.

5. Pre-litigation transfer — NOT PRESENT (timing noted). Jazz sued on its oxybate patents in 21-1138 / 21-691 in May 2021; the intra-group recording is 2020-12-15, i.e., ~5 months earlier. However, the transferee is the operating NDA holder, the step mirrors Jazz's own 2013–2014 recordings on other oxybate patents, and no asserter-entity was interposed. So the timing coincidence does not evidence "arranging the chain to enable assertion."

6. Bankruptcy fire-sale — NOT PRESENT. Jazz is a solvent, publicly listed operating company (parent 10-K / 8-K filings show no Chapter 7/11).

7. Privateering — NOT PRESENT. Jazz asserts in its own name (plaintiffs "Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited"); there is no NPE asserting on Jazz's behalf, and no SEC disclosure of an IP-transfer-to-assertion-vehicle.

8. Defensive aggregator — NOT PRESENT. The chain does not terminate at RPX, AST, LOT, Unified, or OIN. It terminates at Jazz Ireland.

Verdict

Operating-company assertion.

The recorded chain is inventors → Jazz Pharmaceuticals, Inc. (2020-12-14) → Jazz Pharmaceuticals Ireland Limited (2020-12-15), i.e., an employment assignment followed by a single intra-group reorganisation onto the NDA/Orange Book-holding operating entity; the only other event is a group-wide IP security interest to U.S. Bank National Association recorded 2021-05-05 tied to the May 5, 2021 Jazz credit facility (securitization, not a title transfer). No shell entity, no known asserter, no cascading LLC transfers, and no defensive-aggregator terminus appear; Jazz — which ships Xyrem®/Xywav® — sued Avadel directly as a competitor, which is the textbook operating-company-assertion posture. The only residual gap is that reel/frame and correspondent-of-record could not be confirmed in this session, so signal #3 is marked unclear rather than cleared.

Verify at:

• USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search patent number 11077079)
• USPTO Assignment Search (legacy index) — https://assignment.uspto.gov/patent/index.html
• Google Patents legal events for this patent — https://patents.google.com/patent/[US11077079B1](/patent/US11077079B1)/en
• Corroboration of the Jazz two-step pattern (other patents, NOT '079): PTAB IPR2016-00546 / IPR2016-00002 §42.8(b)(1) notices citing Reels 30836/953 and 33480/220 for US 8,772,306, and Reel 30652/164 and 33480/135 for US 9,050,302.

Contradiction flags vs. the prior section: none on ownership — the earlier section's "current assignee = Jazz Pharmaceuticals Ireland Ltd" is consistent with the chain above. Two clarifications: (i) the earlier section called the U.S. Bank entry a "security interest recorded May 5, 2021" — correct, and I now tie it to the specific May 5, 2021 Credit Agreement; (ii) the earlier section listed two Delaware dockets (21-cv-01138 and 21-cv-00487) — consistent with the Google Patents litigation links, and ownership is unaffected either way.

I'll research the prior art references cited on the face of US 11,077,079 and in its prosecution record.

Let me get the full "References Cited" list from the '079 patent's front page.

Let me pull the full front-page reference lists and prosecution citations for the '079 patent specifically.

Prior Art Analysis — US 11,077,079 B1

Method note (read first). I searched for the specific number 11077079 and anchored on the authoritative Google Patents full text you supplied. Two structural limits on what I can state with confidence:

1. The "References Cited" front page of the '079 is largely a carry-over from the grandparent US 10,398,662 / parent chain. The front-page list I could retrieve in full is the one printed on the identically-specified family member US 11,147,782 B1 (same spec, same IDS). I use that as the reconstruction of the '079 list and flag it as reconstruction, not the literal '079 front page.
2. I could not open USPTO PatentCenter/PAIR in this session, so I cannot quote the examiner's actual § 102/§ 103 rejections or the Notice of Allowance reasons. Nothing below should be read as a statement of what the examiner applied — only what is cited and what it could reach.

This section builds on the earlier ones (bibliographic, litigation, PTAB, assignment) and does not repeat them. The central cross-reference point from those sections stands and matters here: the '079 specification is a resinate disclosure, but the granted claims 1/10 are sachet-based method-of-treatment claims. That mismatch drives which cited art is actually § 102-relevant.

A. Why the "relevant prior art" splits in two

Because the asserted claims recite (a) narcolepsy/cataplexy-EDS, (b) a single daily dose equivalent to 4.0–12.0 g sodium oxybate, (c) opening a sachet containing a solid oxybate formulation, mixing with water, and orally administering, and (d) an immediate-release + controlled-release formulation (no resin limitation):

• The big block of GHB/ion-exchange entries on the face is mostly relevant to the specification's resinate disclosure — not to the claims. Under § 102 a reference must disclose every claim element in a single document, so most face entries cannot anticipate the method claims.
• The only cited reference that plausibly reaches claims 1/10 is Liang 2006. The remaining § 102 candidates (Cook family, Allphin 2012, Lebon, Comiskey) were raised in litigation as invalidity art, not applied by the examiner.

B. The reference categories on the face of the '079

(Citations reproduced literally; dates as printed or as reported in the record.)

U.S. Patents (partial — list truncated in retrieval after US 5,955,106):

U.S. Patent Application Publications (on the face):

Foreign documents (from the uspto.report grant listing): CA 2 112 663 (Apr 2002); CA 2 510 289 (Jul 2004); CN 102905688 / 102958930 / 103209966 / 103209967 (2013); EP 0203768, 0235408, 0344704, 0616804, 0635265, 0709087, 1140061, 1316309, plus EP 2760911 (Nov 2017) and EP 1434572 (Dec 2017); GB 922029 (Mar 1963); GB 2295390 (May 1996); and a long JP block (S57-042651, 62-12715, 04-049212, 05-508422, H06-508839, 7-53365, H8-511257, 09-104620, H10-505604, 2001-513552, 2002-533388, 2004-514732, 2007-521231, 2008-512386, 2008-519847, 2008-528571, 2009-53233…).

Non-patent literature on the face (representative): Arena et al., J. Pharm. Sci. 69(3):356-358 (1980); Lettieri & Fung, Res. Commun. Chem. Pathol. Pharmacol. 22(1):107-118 (1978); Snead & Morley, Brain Res. 227(4):579-589 (1981); Vickers, Int. Anesth. Clinic 7(1):75-89 (1969); Mamelak (1977); Singh et al., Fabad J. Pharm. Sci. 32:91-100 (2007); Srikanth et al., J. Sci. Res. 2.3:597-611 (2010); Takka & Gürel, AAPS PharmSciTech 11(1):460-466 (2010); Turnberg, Gut 12(7):544-551 (1971); Davis et al., J. Clin. Invest. 66:1326-1333 (1980); Schiller et al., Aliment. Pharmacol. Ther. 22:971-979 (2005); Dow Amberlite IRN78 / Dowex product data sheets; Duolite AP143/1083 sheet; various Markman transcript/opinion citations (Jazz v. Roxane) and the Xyrem® package insert.

C. Most relevant prior art — § 102 mapping

1. Liang 2006 — the only face reference that plausibly anticipates the independent claims

• Full citation: US 2006/0210630 A1 (Liang et al.), "Controlled Release Compositions of Gamma-Hydroxybutyrate."
• Publication date: September 21, 2006 (qualifies as prior art; well before the contested 2016-02-18 effective date).
• Description: Discloses oral GHB dosage forms comprising an immediate-release component combined with one or more pH-sensitive delayed/controlled-release particles, "supplied as pre-mixed doses," and discloses that the components "can be packaged in individual containers, such as in sachets, sticks, paper bags, or bottles." Also discloses adding an acid (malic, citric, tartaric, ascorbic, oleic, capric, caprylic, benzoic, a polyacid, or acidic ionic resins) and suspending/thickening/gelling agents.
• Claims potentially anticipated: claims 1 and 10 (all elements map except, per the record, an express disclosure of "opening a sachet… mixing the formulation with water… orally administering the mixture," and the 4.0–12.0 g single-daily-dose limitation), with dependent claims 2/11 (night dosing), 3/12, 7/16 (suspension), 8/17 and 9/18 (acid).

Evidentiary caveat you must not skip: the Delaware record is explicit that Liang 2006 was an IDS reference that the Examiner did not apply during prosecution of the '782 ("Although Liang 2006 is listed on the face… it was not cited or discussed by the Examiner"). And Avadel's own expert, Dr. Charman, conceded that Liang does not expressly disclose "opening a sachet containing a gamma-hydroxybutyrate formulation, mixing the formulation with water and orally administering the mixture" — a concession Jazz leaned on in its Motion for Partial Summary Judgment No. 4 of No Anticipation of the '079. So Liang is the strongest single-reference candidate but is defeated on the "sachet/mix-with-water" steps on the current record.

2. Cook family — GHB narcolepsy solutions (relevant to dependent acid/amount claims, not the independents)

• Full citations: US 2002/0077334 A1 (Cook et al., 2002-06-20); US 2007/0270491 A1 (2007-11-22); US 2011/0039929 A1 (2011-02-17); US 2012/0020833 A1 (2012-01-26); US 2012/0202879/0202880 A1 (2012-08-09); US 2013/0143965 A1 (2013-06-06); US 2013/0267595 A1 (2013-10-10); US 2015/0073052 A1 (2015-03-12); US 2017/0224825 A1 (2017-08-10); and the issued "Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy" patents (e.g., US 8,591,922; US 9,539,330) which sit in this lineage.
• Description: Stable aqueous GHB solutions for treating narcolepsy; disclose pH adjustment with malic acid, preservative-free stability, and dosing regimens (historically twice-nightly).
• Claims potentially touched: dependent claims 8/17 and 9/18 (acid selected from malic/citric/tartaric/boric/maleic/phosphoric/benzoic) — Cook discloses malic acid in a GHB narcolepsy solution. It cannot anticipate claims 1/10 because it discloses a liquid solution, not a solid sachet + IR/CR formulation; and note Cook's regimen is not a single 4–12 g daily dose.

3. Allphin 2012 (US 2012/0076865) — Xyrem® solution / malic acid

• Full citation: US 2012/0076865 A1 (Allphin et al.).
• Description: Discloses the Xyrem® sodium-oxybate oral solution and malic-acid pH adjustment to ~7.5.
• Claims potentially touched: same dependent acid claims (8/17, 9/18). Not an anticipation reference for 1/10.

4. Lebon 2013 (US 8,529,954) and Comiskey 2015 (EP 2825188 B1)

• Citations/dates: US 8,529,954 (Lebon et al., issued 2013-09-24); EP 2825188 B1 (Comiskey et al., 2015). Both were asserted by Avadel in litigation as invalidity art against the '079/'782.
• Description: GHB/sodium-oxybate modified-release formulation art (Lebon); GHB formulation/dispensing art (Comiskey). Both predate 2016.
• Claims potentially touched: raised as § 102/§ 103 art for claims 1/10 in Avadel's contentions — but note neither appears on the face of the '079, i.e., neither was considered by the examiner, and both are litigation positions, not adjudicated findings.

5. Resinate art (relevant to the specification, NOT the asserted claims)

• US 4,221,778 (Raghunathan) (9/1980) and US 4,510,128 (Khanna) (4/1985) — the foundational drug–ion-exchange-resin complex patents (Pennwalt). They are on the face and are squarely relevant if/when the specification's resinate embodiments are at issue — but because claims 1/10 recite no resin limitation, these references do not anticipate the granted claims. Flagging them because a reader skimming the face list could wrongly assume they attack the claims.

D. Consolidated § 102 table (potential anticipation only)

E. Explicit uncertainties (do not treat as firm)

• Front-page completeness: the U.S.-patent block was truncated in retrieval after US 5,955,106; the '079's own front page was not directly retrievable, so the list above is reconstructed from the identically-specified US 11,147,782 plus the uspto.report grant listing for 11,077,079. Verify the exact cited list on the '079's own front page/IDS at PatentCenter before relying on it.
• Examiner's reasoning: I could not confirm in this session which references the examiner actually applied under § 102 vs. listed as IDS. The litigation record indicates Liang was IDS-only (not applied); treat any statement that the examiner "rejected over" these references as unverified.
• Reference titles/descriptions for several older U.S. patents (e.g., 4,374,441; 4,738,985; 4,916,161; 4,939,949; 5,415,870; 5,594,030; 5,758,095; 5,955,106) are not independently verified here; I gave dates from the printed list and marked them "—" where I cannot describe them with confidence rather than guess.
• No anticipation has been adjudicated for the '079. Consistent with the earlier section: the '079 was not tried in Delaware; these are potential § 102 candidates, not holdings.

If you want, I can target the '079's own front page and IDS (PatentCenter) and the examiner's Office Actions/Notice of Allowance to (i) replace the reconstructed list with the literal one and (ii) separate references the examiner applied from those merely listed.

I'll research the prior art references identified in the litigation record and verify the claim language before building the § 103 analysis.

Let me get the full prior art list from Avadel's invalidity contentions and the actual claim language.

Obviousness Analysis — U.S. Patent No. 11,077,079 B1 under 35 U.S.C. § 103

Sourcing note. This section builds on the prior-art materials surfaced for this patent (principally Avadel's invalidity contentions as recited in the Delaware pleadings, the Joint Supplemental Claim Construction Appendix, and expert reports, all listed in the searches above) plus the authoritative full text you supplied. Where I could not verify a reference's specific disclosure in this session, I say so rather than characterize it. The '079 patent's validity was never adjudicated — Jazz narrowed the 2024 trial to the '488 and '782 patents, so no court or jury has ruled on § 103 for the '079 claims. Everything below is analysis of the recorded contentions and reference disclosures, not a holding.

1. The claim to be tested

Independent claim 1 (and its parallel claim 10) recite a method of treatment, with these elements:

Critical structural observation (carried forward from the Patent Summary section): none of these elements requires an ion-exchange resin, a resinate, or any polymeric bead. The claims are directed to a sachet-based solid IR + controlled-release oxybate method, so the § 103 inquiry is not bounded by the resinate disclosure that dominates the specification. This matters because § 103 compares the claims to the prior art, not the specification to the prior art.

2. Person of ordinary skill in the art (POSA)

As the parties themselves stipulated in the Delaware action, the POSA is "a member of an inter-disciplinary team of scientists involved in drug research and development" with formulation, pharmacokinetic, and clinical (sleep-medicine) input. That is a sophisticated formulator — a POSA who routinely selects among excipients, coatings, and dosage-form presentations (sachet, suspension, tablet, liquid) and who reads once-nightly-GHB references against the then-marketed Xyrem® twice-nightly paradigm.

3. The prior art of record

Avadel's contentions identified "eighteen alleged prior art references" that "anticipate and/or render obvious, either alone or in combination, the asserted claims." The enumeration I could retrieve lists at least the following (items 1–9); the list continues beyond item 9 in the source. Designations are given exactly as recited:

Two further references appear in the record as part of the same dispute and are directly relevant: Cook 2002 (U.S. Pub. 2002/0077334) — used by the USPTO with Liang 2006 in the rejection of Avadel's own later claim — and Avadel's own publications US 2019/0274990 A1 ("the '990 Publication"), the '866 patent, the '062 patent, and the '321 Application.

4. What the primary reference discloses — Liang 2006

Liang 2006 is the centerpiece. Its own text (quoted in the claim-construction appendix and in Jazz's answer) states:

• It is "directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components." ([0001])
• The express object is to "provid[e] a convenient once nightly or once daily dose regimen" so that "a twice-nightly dosage regimen can be reduced to a single dose." ([0001], [0012])
• "In one of the preferred embodiments, the composition comprises multiple delayed release pellets or beads … and an immediate release component." ([0029])
• The immediate release component can be "in the form of … a sachet" ([0045]) and the IR and CR components can be pre-mixed as particles or powder ([0047], [0048]).
• It discloses a "daily dose of 4.5 to 9 grams of Xyrem®" for narcolepsy patients ([0005]).

Liang therefore expressly discloses elements (a), (b), (f), and (g) and discloses solid, particulate, pre-mixable, once-nightly GHB dosage forms targeting the same indication. It also cites the same "high solubility / hygroscopic / strongly alkaline / very high dose" problem statement that Jazz later relied on.

The only genuine gap in Liang's four corners is the mechanical sequence "opening a sachet … mixing with water … orally administering the mixture" as a claimed method step. Notably, both sides effectively conceded this: Avadel told the USPTO during the '321 prosecution that "Liang do[es] not expressly disclose opening a sachet containing a gamma hydroxybutyrate formulation, mixing the formulation with water and orally administering the mixture," and Avadel's expert Dr. Charman, when deposed, agreed with that statement.

5. § 103 combinations and the articulated motivations

Under KSR Int'l v. Teleflex and the Graham factors, a combination is obvious where a POSA would have had a reason to combine known elements with a reasonable expectation of success, and the motivation need not be found in a single reference. Below are the combinations the record supports, ordered by strength.

Combination A — Liang 2006 alone / + POSA knowledge of sachet dosing (strongest)

• Proposed modification: take Liang's disclosed solid, pre-mixed IR + delayed/controlled-release GHB particles, place them in a sachet, and instruct the patient to open it, suspend in water, and drink — thereby practicing claims 1 and 10.
• Motivation:
  1. Liang itself contemplates a sachet and pre-mixed solid forms ([0045], [0047], [0048]) — the primary reference suggests the very package.
  2. A sachet is the archetypal unit-dose package for a powder/granulate oral suspension, and the art of record (Bladh 2007, esomeprazole sachet; PHARMACEUTICAL SUSPENSIONS 2010; WHO 2012) confirms sachet-for-suspension is a routine, predictable presentation.
  3. The claimed dose (4.0–12.0 g sodium oxybate) matches the Xyrem® 4.5–9 g dose and Liang's own 4.5–9 g disclosure — no new dosing science required.
• Reasonable expectation of success: the sachet/water-mix step is a matter of packaging and patient-instruction, not of unpredictable drug behavior. KSR teaches that combining known elements according to known methods to yield predictable results is obvious; a POSA would expect the same GHB particles to behave identically whether dosed from a sachet or a bottle.

Combination B — Liang 2006 + Lebon 2013

• Proposed combination: Liang's IR + controlled-release GHB formulation plus Lebon's once-daily sustained-release GHB dosage-form teaching and dosing regimens.
• Motivation: Lebon is directed to the same once-daily GHB dosing objective, so it is from the same field, addresses the same problem (avoiding the middle-of-night second dose), and provides overlapping dose ranges. Where two references are directed to the same problem and the same drug, KSR and the DuPont/In re Merck line make the combination a fortiori obvious. The record recites that "Liang 2006 and Lebon 2013 therefore disclose dosing regimens for GHB falling within 4 g to 9 g," which is squarely within claim element (c).

Combination C — Liang 2006 + Comiskey 2015 (high-dose presentation)

• Proposed combination: use Liang's IR/CR GHB with Comiskey's oxybate-formulation teaching on presenting the high dose in a patient-acceptable solid/semi-solid form.
• Motivation: both address the high-dose GHB administrability problem the '079 specification itself emphasizes (Xyrem is a 500 mg/mL, 42 wt% solution; high water burden → bed-wetting). A POSA optimizing a once-nightly GHB product would look to Comiskey for how to handle the high dose.
• ⚠️ Verification flag: I did not retrieve Comiskey 2015's specific disclosure text in this session. Its role and content should be confirmed from EP 2825188 B1 itself before relying on this combination; my description here is limited to its asserted role in the contentions.

Combination D — Liang/Lebon + Bladh 2007 (and/or PHARMACEUTICAL SUSPENSIONS 2010, Bowles 2013) for the sachet / suspension / water-mix limitations

• Proposed combination: add the sachet-for-suspension teaching of Bladh 2007 (a sachet packet formulation for suspension) to Liang's solid IR+CR GHB, yielding claim elements (d)–(e) and dependent 7/16 ("mixture is a suspension").
• Motivation: Bladh 2007 is expressly a sachet/suspension precedent for a drug delivered as a packet suspended in water; PHARMACEUTICAL SUSPENSIONS 2010 supplies the general formulation principles; Bowles 2013 supplies the multiparticulate oral liquid platform. Together they establish that sachet-suspension dosing was a known, predictable, off-the-shelf solution — a classic KSR "known technique to address a known problem."

Combination E — any of the above + Allphin 2012 and/or Balch 2010 for the "acid" limitations (claims 8–9 / 17–18)

• Motivation: the acid limitations require an acid "selected from malic, citric, tartaric, boric, maleic, phosphoric, and benzoic acid." Xyrem® itself is pH-adjusted with malic acid (per the AU 2010352575C1 family text reproduced in the search results: "Xyrem® … contains 500 mg sodium oxybate/ml water, adjusted to pH = 7.5 with malic acid"), and Allphin 2012 (Jazz's own incorporated-by-reference publication) is cited in the record for the oxybate/acid formulation. Balch 2010 shows acid/excipient selection in an extended-release opioid matrix. A POSA would select a pharmaceutically acceptable acid — including malic acid, already used in the commercial GHB product — as a matter of routine optimization.

Combination F — Cook 2002 + Liang 2006 (the actual USPTO-art combination)

• This is the exact pairing the USPTO used to reject Avadel's own later-filed claim ("unpatentable over Liang 2006 in view of … Cook et al."). It is powerful because it shows the Patent Office itself considered "Liang + Cook" a prima facie obvious combination over the same IR+CR + sachet/water-mix subject matter. Avadel's subsequent arguments (stability, microbial growth, GBL degradation, and "teach away from a sachet") persuaded the examiner to withdraw — but those very arguments are the secondary-consideration overlay analyzed in § 7 below.

Combination G — contingent on the priority date: the Avadel publications ('990 Publication / '866 / '062 / '321)

• Avadel's expert put it bluntly: "To the extent the '079 patent has sufficient written description support, the '079 patent is invalid as anticipated by Avadel's '990 Publication," and the '990 Publication discloses treating narcolepsy with an IR + modified-release formulation supplied "in sachets or stick-packs … these sachets can be opened, and its contents mixed with tap water" ('990 at [0362]; claim 1 recites "opening a sachet").
• Timing caveat that cuts both ways: the '990 Publication published Sep. 12, 2019. If the '079 claims are entitled to the Feb. 18, 2016 effective date, the '990 Publication is not prior art (it post-dates the claims) — and Avadel's anticipation theory collapses into its derivation/inventorship theory instead. If, as Avadel contends and as the examiner reportedly found ("there is no support for the claimed subject matter in prov' 889[, t]herefore, the earliest priority for the claimed subject matter is the effective filing date of 02/18/2016"), the claims are limited to a later date, the analysis shifts. Either way, the priority-effective-date fight is the pivot for this family of art.

6. Why a POSA would have been motivated — the synthesized rationale

Drawn together, the record supports this KSR-compliant narrative:

1. Known problem, known solution. The art (Liang's own [0005]–[0007], the '079 specification, Xyrem® labeling, Lebon, Comiskey) uniformly identifies the same problem: GHB is high-dose, highly soluble, and requires an inconvenient twice-nightly, wake-to-redose regimen.
2. Known combined formulation. Liang squarely teaches reducing twice-nightly to once-nightly using IR + delayed/controlled-release GHB particles — i.e., element (g) plus the therapeutic goal.
3. Known unit-dose package. Sachet-for-suspension dosing was routine (Bladh 2007; WHO 2012; Bowles 2013; PHARMACEUTICAL SUSPENSIONS 2010), and Liang itself names a sachet.
4. Predictable results. Assembling these known elements yields nothing more than the expected combination of their known functions — the KSR paradigm of predictable, obvious subject matter.
5. Same field, same drug, same indication. Liang, Lebon, Comiskey, and Allphin are all GHB/oxybate/narcolepsy references; the combination is within a single, well-defined technical field — the strongest fact pattern for obviousness.

7. Countervailing considerations a validity defense would raise

A rigorous analyst must supply the other side, because these are exactly the points that kept the case live and that defeated the USPTO rejection of Avadel's own claim:

1. Teaching away / "problematic" sachet. Avadel told the USPTO — under oath — that the prior art "teaches away from a sachet as currently claimed," that a POSA would "abandon the 'problematic' sachet formulation in favor of a purely liquid formulation," and that "there are known problems of instability, microbial growth, and/or degradation of the GHB active ingredient into GBL." A finding of teaching away, if credited, defeats the sachet-limitation combination. Jazz's judicial-estoppel theory is built precisely on these inconsistent positions (its Second Amended Answer asks the court to estop Avadel under §§ 102/103). (Note: this is a party's litigation position, not an adjudicated finding, and the court never reached it for the '079 claims.)
2. Unpredictability of GHB formulations. Avadel repeatedly told the USPTO (in its '062/'866/'986/'795 prosecutions) that "there is no reasonable predictability with respect to GHB formulations," that PK "could not be predicted" from Liang, and that using Liang "to guess the in vivo pharmacokinetic profile … would be pure speculation." Those admissions, if imported into the § 103 analysis, undermine the "reasonable expectation of success" prong — but they were made by Avadel, the challenger, and may be estopped from being asserted.
3. Unexpected results / secondary considerations. Jazz would point to the commercial once-nightly advance and to the long-felt need for eliminating the middle-of-night dose. Any such evidence must have a nexus to the claimed subject matter (sachet + IR/CR method) to carry weight; the record I retrieved does not establish such a nexus, and no court has evaluated it.
4. The § 112/priority overlay does real work here. The examiner's own finding that the '889 provisional lacks support for the claims (particularly the "sachet" and "controlled release component" limitations) means the effective filing date is contested (Feb. 18, 2016 vs. Dec. 10, 2020). If the later date governs, more art (including the '990 Publication) becomes available; if the earlier date governs, the sachet/PK-gap story sharpens the pedagogical weight of Liang + sachet art. Either way, § 112 (written description/enablement), not § 103, was the primary theory the parties actually litigated — and the district court's in-limine ruling (Feb. 14, 2024) that certain unclaimed functional limitations need not be enabled shows how entangled the § 103 and § 112 theories were.

8. Bottom line

• Strongest § 103 theory: Liang 2006 (expressly teaching once-nightly, IR + delayed/controlled-release GHB) in view of the routine sachet-suspension art (Bladh 2007, Pharmaceutical Suspensions 2010, Bowles 2013), optionally with Lebon 2013 (once-daily GHB dosing) and/or Cook 2002 — with Allphin 2012 and the Xyrem® malic-acid practice supplying the acid limitations. This combination maps onto every element of claims 1 and 10, and onto dependent claims 2–9 and 11–18, with a KSR-sufficient articulated motivation (same field, same problem, same drug, predictable packaging step).
• The decisive vulnerabilities of that theory are (i) the alleged teaching away from sachets for GHB and (ii) the unpredictability of GHB formulations — both of which Avadel itself argued to the USPTO, creating Jazz's judicial-estoppel counterattack. Those, plus the contested priority date, are where the '079's § 103 fate actually turns.

Confidence & limitations

• High confidence in the claim text (quoted from the Joint Supplemental Claim Construction Appendix and confirmed by the complaint analysis) and in Liang 2006's disclosure (quoted directly from the reference's own paragraphs).
• High confidence that no court ever adjudicated § 103 for the '079 claims, and that the 2024 trial was narrowed to the '488/'782 — consistent with the prior Litigation section.
• Flagged as unverified in this session: the specific disclosures of Comiskey 2015, Lebon 2013, Balch 2010, and Bowles 2013 (I have their asserted roles but not their quoted text), and the full enumeration of all eighteen references (I retrieved items 1–9 plus Cook 2002 and the Avadel publications).
• No invention: I did not fabricate reference content or contentions that did not surface. To lock this analysis down for any filing, pull the actual paragraph-level citations from Avadel's 1-14-22 Contentions (Ex. F in the Delaware record), the Joint Supplemental Claim Construction Appendix (D.I. 315-1), and the Charman opening/second-supplemental reports (D.I. 357; D.I. 581), which contain the element-by-element charts.

Sources (as surfaced): Joint Supplemental Claim Construction Appendix, D.I. 315-1, Jazz v. Avadel, C.A. No. 21-691-GBW (Georgetown Litigation Tracker); Jazz's First/Second Amended Answers to Avadel's Counterclaims (Ex. F, Avadel 1-14-22 Initial Invalidity Contentions); D. Del. D.I. 357 (Klibanov/Charman anticipation contentions re '990 Publication); D. Del. D.I. 459 and D.I. 526.1 (Feb. 14, 2024 memorandum opinion and in-limine rulings); US 2006/0210630 A1 (Liang 2006); Avadel investor disclosures summarizing the complaints, trial narrowing, and Oct. 2025 settlement.